ALYFTREK Is Here - And It Changes Everything for 95% of CF Patients

For families living with cystic fibrosis, December 2024 brought news that felt like a turning point: the FDA approved ALYFTREK - a once-daily, next-generation CFTR modulator from Vertex Pharmaceuticals. Then in April 2026, the story got even bigger. The FDA expanded the labels for both ALYFTREK and Trikafta, making CFTR modulator therapy available to approximately 95% of all people with cystic fibrosis in the United States.

That number deserves a moment to land. Ninety-five percent.

What Is ALYFTREK?

ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) is a triple-combination CFTR modulator - meaning it contains three active compounds that work together to correct the underlying protein defect in CF. Like Trikafta, it targets the root cause of the disease rather than just managing symptoms. But ALYFTREK improves on Trikafta in two important ways: it is taken once daily instead of twice, and it demonstrated non-inferiority to Trikafta across key clinical endpoints in a Phase 3 trial of more than 1,000 patients across 200+ sites in 20 countries.

The label expansion approved in April 2026 was supported by data from 564 genetic variants demonstrating response to ALYFTREK - the most comprehensive mutation coverage in CF treatment history.

What the 95% Number Actually Means

When Trikafta was first approved in 2019, it was a landmark moment - the first therapy that worked for a large percentage of CF patients. But "large percentage" still left thousands behind. The combination of ALYFTREK and expanded Trikafta labeling now covers the broadest range of CF-causing mutations ever approved, giving physicians more options and patients more access.

For a parent of a child with CF - like the families that make up the heart of CF Bites Foundation - this is the kind of news that rewrites the conversation. The question is no longer "will my child have access to treatment?" For 95% of CF patients, the answer is now yes.

The 5% Who Are Still Waiting

We should name the work that remains. Approximately 5% of people with CF have mutations where CFTR modulators don't help - either because their cells produce no functional CFTR protein at all, or because their specific mutation doesn't respond to available drugs. For those patients, gene therapy and mRNA-based approaches are the most promising frontier. (We've covered those in separate posts.)

But let's not let perfect be the enemy of extraordinary. The approval of ALYFTREK and its expanded label is a genuine milestone in the history of this disease - one that was only possible because of decades of research funding, patient advocacy, and community-driven fundraising.

Why CF Bites Keeps Showing Up

Every dollar raised at a CF Bites gala goes directly to the Cystic Fibrosis Foundation - the organization that has helped fund more than 50% of all CF therapies brought to market, including ALYFTREK. The connection between a Halloween party in Charleston and a once-daily pill that reaches 95% of CF patients is direct. It runs through the CFF's research pipeline, and it runs through communities like ours that refuse to stop showing up.

Aubin is seven years old. The world she is growing up in is different from the one her diagnosis first described - because people kept fighting for it. That fight continues.